| Neuromyelitis Optica
Enspryng vs Uplinza
Side-by-side clinical, coverage, and cost comparison for neuromyelitis optica.Deep comparison between: Enspryng vs Uplizna with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUplizna has a higher rate of injection site reactions vs Enspryng based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uplizna but not Enspryng, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Enspryng
Uplizna
At A Glance
SC injection
Every 4 weeks
IL-6 receptor antagonist
IV infusion
Every 6 months
CD19-directed cytolytic antibody
Indications
- Neuromyelitis Optica
- Neuromyelitis Optica
- Immunoglobulin G4-Related Disease
- Myasthenia Gravis, Generalized
Dosing
Neuromyelitis Optica Loading dose of 120 mg SC at Weeks 0, 2, and 4; maintenance dose of 120 mg every 4 weeks.
Neuromyelitis Optica, Immunoglobulin G4-Related Disease, Myasthenia Gravis, Generalized Initial dose: 300 mg IV infusion, followed 2 weeks later by a second 300 mg IV infusion; subsequent doses: 300 mg IV infusion every 6 months starting 6 months from first infusion; premedicate with a corticosteroid (methylprednisolone 80-125 mg IV), antihistamine (diphenhydramine 25-50 mg oral), and antipyretic (acetaminophen 500-650 mg oral) before each infusion; dilute in 250 mL 0.9% Sodium Chloride and infuse over approximately 90 minutes.
Contraindications
- Known hypersensitivity to satralizumab or any inactive ingredient
- Active Hepatitis B infection
- Active or untreated latent tuberculosis
- History of life-threatening infusion reaction to inebilizumab-cdon or any excipient
- Active hepatitis B infection (confirmed by positive HBsAg and anti-HBV tests)
- Active or untreated latent tuberculosis
Adverse Reactions
Most common (>=15%) nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue, nausea
Serious infections, elevated liver enzymes, decreased neutrophil counts, hypersensitivity reactions
Most common (>=10%) Urinary tract infection, nasopharyngitis, infusion-related reaction, arthralgia, headache, lymphopenia
Serious Infusion reactions, infections, reduction in immunoglobulins
Pharmacology
IL-6 receptor antagonist; recombinant humanized anti-human IL-6 receptor monoclonal antibody that inhibits IL-6-mediated signaling by binding to soluble and membrane-bound IL-6 receptors.
CD19-directed humanized afucosylated IgG1 monoclonal antibody; binds CD19 on pre-B and mature B lymphocytes and induces antibody-dependent cellular cytolysis, depleting B-cell counts within 8 days of infusion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Enspryng
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (3/12) · Qty limit (9/12)
Uplizna
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Enspryng
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Uplizna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Enspryng
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Uplizna
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Neuromyelitis Optica Spectrum Disorder (NMOSD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Amgen By Your Side Copay Assistance Program: UpliznaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EnspryngView full Enspryng profile
UpliznaView full Uplizna profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.